All In Biotech

Drug Trial Radar · NCT06811116

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE)

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
NIH
First posted
Feb 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating β-catenin-mutated metastatic hepatocellular carcinoma.

Conditions

  • Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood collection

  • Cabozantinib S-malateDrug

    Given PO

  • Imaging ProcedureProcedure

    Undergo imaging scans

  • SapanisertibDrug

    Given orally (PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities and incidence of adverse eventsTime frame: From registration to disease progression or death due to any cause, assessed up to 2 years
  2. Progression free survival (PFS)Time frame: From registration to disease progression or death due to any cause, assessed up to 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.